OBJECTIVE: To carry out a cost-utility analysis of the treatment of relapsing-remitting @entity15 (RRMS) with @entity1638 ( @entity1638 ) or interferon beta (all, avonex, rebif and betaferon). METHODS: A pharmacoeconomic Markov model was used to compare treatment options by simulating the life of a hypothetical cohort of @entity1 aged 30, from the societal perspective. The transition probabilities, utilities, resource utilisation and costs (direct and indirect) were obtained from Spanish sources and from bibliography. Univariant sensitivity analyses of the base case were performed. RESULTS: In the base case analysis, the average cost per @entity1 ( @entity7634 in 2001) for a lifetime treatment, considering a life expectancy of 53 years, would be 1,243,906 @entity7634 ( @entity7634 ), 1,818,149 @entity7634 , 1,763,263 @entity7634 , 1,987,153 @entity7634 and 1,704,031 @entity7634 with @entity1638 , all interferons, avonex, rebif and betaferon, respectively. Therefore, the saving with @entity1638 would range between 460,000 and 737,000 @entity7634 approximately. The quality-adjusted life years (QALY) obtained with @entity1638 or interferons would be 10.977 and 6.917, respectively, with an average gain of 4.060 QALY @entity1 with @entity1638 . The sensitivity analyses confirmed the robustness of the base case. The interferons would only be superior to @entity1638 in the unlikely hypothetical case that they delay the progression of the illness by 20% more than that actually observed in clinical trials. CONCLUSIONS: For a typical @entity1 with RRMS, treatment with @entity1638 would be more efficient than interferons and would dominate (would be more efficacious with lower costs) interferon beta.

[Cost-utility analisys of @entity15 treatment with XXXX or interferon beta in Spain].

@entity1 :: ('9606', 'Species') :: ['women', 'patient'] @entity7634 :: ('9319', 'Species') :: ['euros', 'euro'] @entity15 :: ('MESH:D009103', 'Disease') :: ['multiple sclerosis'] @entity1638 :: ('MESH:C089995', 'Chemical') :: ['copaxone', 'glatiramer acetate']
@entity1638 :: (MESH:C089995,Chemical) :: ['glatiramer acetate']
